The Goldilocks for chronic weight management—Balancing quantity with quality of weight loss

Abstract Anti‐obesity medications have reached new heights in terms of efficacy, with presently available pharmacological options almost reaching the efficacy of the surgical techniques, and thus these are starting to fill the treatment void. Because of the increased weight loss efficacy, benefits on a host of obesity complications are being reported, with prevention of diabetes, reduction of liver and cardiovascular complications and improvements in osteoarthritis among the prominent features. On the other hand, present anti‐obesity strategies also lead to loss of lean and bone mass, and while the consequences hereof are only beginning to present, they are highly likely to be of importance in a target population that contains a large number of elderly and potentially frail individuals. Therefore, there is a need to address the issue of weight loss quality, both in the context of existing possibilities, but especially in the context of the myriad of novel anti‐obesity medications on the horizon.